| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
This compound does not possess a specific biological target; its primary function is as a chemical building block for peptide synthesis. As a protected dipeptide, it is used to introduce the Lys-Ser dipeptide motif into peptides with conformational constraint. The pseudo-proline modification reversibly protects the Ser residue and disrupts β-sheet formation during synthesis, overcoming aggregation issues. This compound is valuable for designing structurally constrained peptides with enhanced stability and defined bioactivity.
|
|---|---|
| ln Vitro |
This compound is not a biological agent and does not exhibit direct in vitro biological activity in a pharmacological sense. Its value lies in its chemical utility as a specialized building block for improving peptide synthesis efficiency and introducing conformational constraints. It has been shown to exhibit potent biological activity, but this is associated with the final peptide products, not the protected intermediate itself.
|
| ln Vivo |
Fmoc-Lys(Boc)-Ser(psi(Me,Me)pro)-OH is not administered in vivo as a therapeutic agent. It is a research chemical utilized as a building block in peptide synthesis. The final deprotected peptide product, not this protected intermediate, would be the subject of in vivo pharmacological testing for therapeutic efficacy and safety. The compound is for research use only and is not intended for human or veterinary therapeutic applications.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable to this compound as it is not biologically active. Its use is in peptide synthesis. A typical protocol involves its use as a building block in Fmoc SPPS to introduce the Lys-Ser dipeptide motif while suppressing aggregation. The pseudo-proline is stable during chain assembly and can be removed under TFA treatment during final cleavage. The Fmoc group is removed with base (e.g., piperidine) to allow for coupling with the next amino acid, and the Boc group can be selectively removed under acidic conditions for side-chain modifications.
|
| Cell Assay |
This compound is not used in cell-based assays as a therapeutic agent. Its role is as a research chemical and building block for peptide synthesis. It should be stored as a powder at -20°C or below. It is a solid. Purity is typically ≥95%. The compound is soluble in common organic solvents such as DMF and DMSO. The product is for research purposes only and is not intended for human or veterinary use.
|
| Animal Protocol |
In vivo animal experiments do not involve this compound as a test article. It is a chemical intermediate used in the synthesis of peptide-based drug candidates. If a researcher synthesizes a therapeutic peptide using this building block, that final deprotected and purified peptide product would be subjected to animal testing. The protected dipeptide itself is never administered to animals as a test compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to this compound as it is not a drug. It is a small molecule (MW 595.68 g/mol) with the formula C32H41N3O8. Its properties are relevant for chemical handling and storage rather than for systemic exposure or ADME studies. The protecting groups (Fmoc, Boc, pseudo-proline) are designed for synthetic utility, not for bioavailability.
|
| Toxicity/Toxicokinetics |
The toxicity of this compound is not extensively documented, as it is a research chemical not intended for human or veterinary use. As with all Fmoc-protected amino acids, standard laboratory safety precautions should be followed, including handling in a well-ventilated area with appropriate personal protective equipment (gloves, lab coat, safety glasses). The compound should be stored as a powder at -20°C or below and protected from moisture. It is not intended for diagnostic, therapeutic, or other medical applications.
|
| Additional Infomation |
Fmoc-Lys(Boc)-Ser(psi(Me,Me)pro)-OH is a protected dipeptide building block used in solid-phase peptide synthesis. The ψ(Me,Me)Pro motif acts as a peptide bond isostere, enforcing a trans conformation and improving conformational stability. The pseudo-proline modification is a powerful tool for overcoming aggregation in Fmoc SPPS. This compound is valuable for designing structurally constrained peptides with enhanced stability and defined bioactivity. It is not a pharmaceutical and has no clinical trials or approved therapeutic status.
|
| Molecular Formula |
C32H41N3O8
|
|---|---|
| Molecular Weight |
595.68
|
| Exact Mass |
595.289
|
| CAS # |
957780-54-0
|
| PubChem CID |
75534996
|
| Appearance |
White to off-white solid powder
|
| Density |
1.231±0.06 g/cm3 (20 °C, 760 mmHg)
|
| Boiling Point |
809.3±65.0 °C (760 mmHg)
|
| LogP |
5.356
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
43
|
| Complexity |
989
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1(N([C@@H](CO1)C(=O)O)C(=O)[C@H](CCCCNC(=O)OC(C)(C)C)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24)C
|
| InChi Key |
SCQJDNYUMSKATK-UIOOFZCWSA-N
|
| InChi Code |
InChI=1S/C32H41N3O8/c1-31(2,3)43-29(39)33-17-11-10-16-25(27(36)35-26(28(37)38)19-42-32(35,4)5)34-30(40)41-18-24-22-14-8-6-12-20(22)21-13-7-9-15-23(21)24/h6-9,12-15,24-26H,10-11,16-19H2,1-5H3,(H,33,39)(H,34,40)(H,37,38)/t25-,26-/m0/s1
|
| Chemical Name |
(4S)-3-[(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]-2,2-dimethyl-1,3-oxazolidine-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6788 mL | 8.3938 mL | 16.7875 mL | |
| 5 mM | 0.3358 mL | 1.6788 mL | 3.3575 mL | |
| 10 mM | 0.1679 mL | 0.8394 mL | 1.6788 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
